The latest announcement is out from GlaxoSmithKline ( (GB:GSK) ).

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

GSK Egypt posted non-consolidated net profits after tax of EGP 71.33 million in H1-25, an annual drop from EGP 99.54 million.

Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...

Mumbai: In a major relief for Thermo Fisher Scientific India Pvt. Ltd., the Income Tax Appellate Tribunal (ITAT), Mumbai "H" ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.97. The company’s shares opened today at p1,424.50. Take advantage of TipRanks ...

Glaxo (GSK) delivered earnings and revenue surprises of +9.82% and +3.25%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Glaxosmithkline Share Chat. Chat About GSK Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary.

Jiangsu Hengrui Pharmaceuticals' shares surged 10% to a 4-year high after licensing HRS-9821 and 11 programs to GlaxoSmithKline. GSK will pay $500 million upfront, with potential milestones reaching ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline today and set a price target of £13.48. The company’s shares closed today at p1,344.00.